• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.早期前列腺癌患者经前列腺按摩获取的前列腺细胞中基因不稳定的临床相关性
Br J Cancer. 2005 Jan 31;92(2):236-40. doi: 10.1038/sj.bjc.6602311.
2
Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.前列腺癌患者肿瘤组织与血液中等位基因失衡的微卫星分析
BJU Int. 2008 Jul;102(2):253-8. doi: 10.1111/j.1464-410X.2008.07600.x. Epub 2008 Jul 1.
3
The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.尿DD3(PCA3)mRNA与前列腺特异性抗原(PSA)mRNA联合作为前列腺癌的分子标志物。
Biomarkers. 2009 Jun;14(4):235-43. doi: 10.1080/13547500902807306.
4
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.良性前列腺增生症和前列腺癌患者的血清与尿液前列腺特异性抗原比值
Anticancer Res. 2000 Nov-Dec;20(6D):4995-6.
5
Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.基于序列特异性RNA捕获获得的尿液PCA3/PSA比值,提高前列腺癌诊断的敏感性和特异性。
Oncol Rep. 2015 Nov;34(5):2439-44. doi: 10.3892/or.2015.4266. Epub 2015 Sep 9.
6
A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.尿液三基因检测 panel 提高了 PSA 检测前列腺癌的特异性。
Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.
7
Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.用于测量前列腺良性增生和腺癌中前列腺特异性抗原mRNA表达的实时逆转录聚合酶链反应。
Clin Chem Lab Med. 2003 Mar;41(3):261-5. doi: 10.1515/CCLM.2003.040.
8
Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.前列腺特异性抗原(蛋白质和信使核糖核酸)分析在前列腺癌鉴别诊断及分期中的应用
Clin Chim Acta. 1997 Sep 8;265(1):65-76. doi: 10.1016/s0009-8981(97)00105-8.
9
[Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].[采用双重TaqMan逆转录聚合酶链反应法检测尿液DD3/PSA信使核糖核酸比值及其初步应用进展]
Zhonghua Yi Xue Za Zhi. 2008 Jan 22;88(4):261-4.
10
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.基于DD3(PCA3)的分子尿液分析用于前列腺癌的诊断。
Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6. doi: 10.1016/s0302-2838(03)00201-x.

引用本文的文献

1
Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid.使用5-氨基酮戊酸对排出尿液中的前列腺癌细胞进行分光光度法光动力诊断。
Lasers Med Sci. 2018 Sep;33(7):1557-1563. doi: 10.1007/s10103-018-2519-4. Epub 2018 May 4.
2
MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.MiR-193b启动子甲基化可准确检测尿沉渣中的前列腺癌,而miR-34b/c或miR-129-2启动子甲基化可界定临床侵袭性肿瘤的亚组。
Mol Cancer. 2017 Jan 31;16(1):26. doi: 10.1186/s12943-017-0604-0.
3
Current early diagnostic biomarkers of prostate cancer.前列腺癌当前的早期诊断生物标志物。
Asian J Androl. 2014 Jul-Aug;16(4):549-54. doi: 10.4103/1008-682X.129211.
4
Urine markers and prostate cancer.尿液标志物与前列腺癌。
Cent European J Urol. 2011;64(1):9-14. doi: 10.5173/ceju.2011.01.art2. Epub 2011 Mar 18.
5
Markers for detection of prostate cancer.用于前列腺癌检测的标志物。
Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125.
6
Toward the detection of prostate cancer in urine: a critical analysis.迈向尿液前列腺癌检测:批判性分析。
J Urol. 2013 Feb;189(2):422-9. doi: 10.1016/j.juro.2012.04.143. Epub 2012 Sep 24.
7
Urine biomarkers in prostate cancer.前列腺癌的尿液生物标志物。
Nat Rev Urol. 2010 Feb;7(2):101-9. doi: 10.1038/nrurol.2009.261. Epub 2010 Jan 12.
8
Newer potential biomarkers in prostate cancer.前列腺癌中更新的潜在生物标志物。
Rev Urol. 2007 Fall;9(4):207-13.

本文引用的文献

1
Allelic losses in localized prostate cancer: association with prognostic factors.局限性前列腺癌中的等位基因缺失:与预后因素的关联
J Urol. 2003 Oct;170(4 Pt 1):1394-7. doi: 10.1097/01.ju.0000083329.89215.91.
2
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.基于DD3(PCA3)的分子尿液分析用于前列腺癌的诊断。
Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6. doi: 10.1016/s0302-2838(03)00201-x.
3
Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.
Clin Cancer Res. 2001 Oct;7(10):3139-43.
4
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.通过 GSTP1 基因高甲基化对尿液中前列腺癌进行分子检测。
Clin Cancer Res. 2001 Sep;7(9):2727-30.
5
The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.前列腺按摩后利用端粒酶活性检测前列腺癌细胞。
J Urol. 2001 May;165(5):1802-5.
6
Molecular genetics of prostate cancer.前列腺癌的分子遗传学
Ann Med. 2001 Mar;33(2):130-41. doi: 10.3109/07853890109002068.
7
Prostate-specific antigen: current status.前列腺特异性抗原:现状
CA Cancer J Clin. 1999 Sep-Oct;49(5):264-81. doi: 10.3322/canjclin.49.5.264.
8
Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer.
Eur J Intern Med. 2001 Feb;12(1):17-19. doi: 10.1016/s0953-6205(00)00134-5.
9
Deletion at 13q21 is associated with aggressive prostate cancers.13号染色体长臂21区的缺失与侵袭性前列腺癌相关。
Cancer Res. 2000 Jul 15;60(14):3880-3.
10
Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma.原发性和转移性前列腺腺癌中12P12 - 13位点杂合性缺失
J Urol. 2000 Jul;164(1):192-6.

早期前列腺癌患者经前列腺按摩获取的前列腺细胞中基因不稳定的临床相关性

Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.

作者信息

Thuret R, Chantrel-Groussard K, Azzouzi A-R, Villette J-M, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O

机构信息

CeRePP-EA3104, University Paris 7, France.

出版信息

Br J Cancer. 2005 Jan 31;92(2):236-40. doi: 10.1038/sj.bjc.6602311.

DOI:10.1038/sj.bjc.6602311
PMID:15655554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2361859/
Abstract

We investigated whether genetic lesions such as loss of heterozygosity (LOH) are detected in prostatic cells obtained by prostatic massage during early diagnosis of prostate cancer (CaP) and discussed their clinical relevance. Blood and first urine voided after prostatic massage were collected in 99 patients with total prostate-specific antigen (PSA) between 4 and 10 ng ml(-1), prior to prostate biopsies. Presence of prostatic cells was confirmed by quantitative RT-PCR analysis of PSA mRNA. Genomic DNA was analysed for LOH on six chromosomal regions. One or more allelic deletions were found in prostatic fluid from 57 patients analysed, of whom 33 (58%) had CaP. Sensitivity and specificity of LOH detection and PSA free to total ratio <15% for positive biopsy were respectively 86.7 and 44% (P=0.002) for LOH, and 55 and 74% (P=0.006) for PSA ratio <15%. Analysis of LOH obtained from prostatic tumours revealed similar patterns compared to prostatic fluid cells in 86% of cases, confirming its accuracy. The presence of LOH of urinary prostatic cells obtained after prostatic massage is significantly associated with CaP on biopsy and may potentially help to identify a set of patients who are candidates for further prostate biopsies.

摘要

我们研究了在前列腺癌(CaP)早期诊断过程中,通过前列腺按摩获取的前列腺细胞中是否能检测到杂合性缺失(LOH)等基因损伤,并讨论了它们的临床相关性。在99例总前列腺特异性抗原(PSA)在4至10 ng/ml(-1)之间的患者进行前列腺活检之前,收集了前列腺按摩后的血液和首次排尿尿液。通过对PSA mRNA进行定量RT-PCR分析来确认前列腺细胞的存在。对六个染色体区域的基因组DNA进行了LOH分析。在分析的57例患者的前列腺液中发现了一个或多个等位基因缺失,其中33例(58%)患有CaP。活检阳性时,LOH检测的敏感性和特异性以及游离PSA与总PSA比值<15%,LOH分别为86.7%和44%(P=0.002),PSA比值<15%分别为55%和74%(P=0.006)。对前列腺肿瘤中获得LOH的分析显示,86%的病例与前列腺液细胞的模式相似,证实了其准确性。前列腺按摩后获得的尿前列腺细胞中LOH的存在与活检时的CaP显著相关,可能有助于识别一组适合进一步进行前列腺活检的患者。